CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Case Report of Two Patients with Refractory HIV-Related 1 B-Cell Lymphoma Treated with the Monoclonal Antibody 2 Glofitamab for Secondary Central Nervous System 3 Involvement
Provisionally accepted
- the second affiliated hospital of air force medical university, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Diffuse large B-cell lymphoma (DLBCL), the most common type of human 13 immunodeficiency virus (HIV) -related lymphoma, is associated with a high risk of 14 central nervous system (CNS) involvement. Studies have shown that CD20×CD3 15 bispecific antibodies have significant therapeutic efficacy in refractory B-cell 16 lymphoma. Preliminary reports indicate that the monoclonal antibody glofitamab can 17 penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients 18 by activating T lymphocytes. This report presents preliminary clinical evidence on the 19 use of glofitamab in HIV-positive patients with secondary CNS lymphoma.
Keywords: Hiv-associated lymphoma, Secondary central nervous system lymphoma, glofitamab, case report, efficacy
Received: 05 Sep 2025; Accepted: 18 Dec 2025.
Copyright: © 2025 Ji, Gao, Wei, Hao and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Weiwei Qin
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.